(Reuters) – BeyondSpring said on Wednesday the U.S. Food and Drug Administration had declined to approve its drug candidate, plinabulin, for the prevention of chemotherapy-induced neutropenia, which occurs due to a lower white blood cell count.
(Reporting by Amruta Khandekar; Editing by Maju Samuel)
